Shares tumbled 7.8% to $23.09 this morning after Hims & Hers announced a $300 million convertible senior notes offering due 2032 — its second major debt raise in just over a year — landing at the worst possible moment for a stock already reeling from an earnings miss and a painful business pivot.

  • A Second Convertible Deal Piles Onto $1 Billion Already Outstanding. The company is selling $300 million in convertible notes due 2032, with an option for buyers to purchase an additional $45 million. This arrives on top of $1.0 billion of 0% convertible notes due 2030 already on the books. Convertible notes are a form of debt that can eventually turn into stock — meaning if the share price rises enough, new shares get created, shrinking existing investors' slice of the pie. The market reacts to the potential dilution; investors often view convertible debt as a precursor to equity dilution, which can decrease existing shareholders' value.

  • The Money Is Earmarked for a Massive Overseas Bet. Hims intends to use proceeds to preserve financial flexibility while expanding internationally, investing in technology and fulfillment infrastructure, and scaling AI capabilities. A major target: the up-to-$1.15 billion acquisition of Australia-based Eucalyptus , which requires approximately $240 million in cash at closing, with remaining payments structured over 18 months plus earn-outs through early 2029. This deal is expected to close mid-2026.

  • The Timing Couldn't Be Worse for Shareholders. Hims posted Q1 2026 revenue of $608.1 million against a consensus of $616.85 million, and reported diluted EPS of -$0.40 versus the Street's $0.03 expectation.

Gross margins compressed from 73% to 65% as the company pivots away from high-margin compounded weight-loss drugs toward branded alternatives following FDA and legal pressure. The stock has plunged from a 52-week high of $70.43 to today's $23.09 — a roughly 67% decline.

  • Analyst Sentiment Is Divided, But the Bar Keeps Dropping. JPMorgan trimmed its price target to $33, while Canaccord raised its target to $32 with a Buy rating.

Bank of America cut its target to $30 from $32, keeping a Neutral rating. With roughly 228 million shares outstanding and a market cap now hovering near $5.3 billion, the $300 million raise represents a meaningful claim on future equity at a moment when the company's profitability story has evaporated. The central question: can international revenue — which surged 969% year over year — grow fast enough to justify the dilution before patience runs out?